耐碳青霉烯类鲍氏不动杆菌基因群检测研究

Gene cluster detection of carbapenem-resistant Acinetobacter baumannii

目的探讨耐碳青霉烯类鲍氏不动杆菌(CRAB)基因群和合理用药的相关性,为临床用药提供参考依据。方法选取2014年1月-2015年7月无锡市第二人民医院,耐碳青霉烯类鲍氏不动杆菌感染阳性患者217例,进行PCR基因序列的分析;记录用药情况和预后,对基因群和联合用药做相关性分析。结果 67株扩增出OXA-23型引物预期长度产物;169株扩增出OXA-51(66)型引物预期长度产物;预后与是否联合用药做交叉表显示,预后和联合用药差异有统计学意义(P<0.05)。结论耐碳青霉烯类鲍氏不动杆菌基因群OXA-51(66)的阳性与阴性表达,检测其基因序列对于临床联合用药具有一定的提示价值。

OBJECTIVE To investigate the correlation between the gene group of carbapenem resistant Acinetobacter baumannii（CRAB）and the combination medication,so as to provide references for clinical medication.METHODS A total of 217 cases of carbapenem resistant A.baumannii positive patients of Wuxi Second People＇s Hospital from Jan.2014 to Jul.2015 were selected.PCR method was used to carry out sequence amplification.The drug use conditions and the prognosis were recorded,and correlation analysis of gene group and combination medication was carried out.RESULTS There were 67strains（31%）to amplify out of OXA-23 primer expected length product,and 169strains（78%）to amplify out of OXA-51（66）primer expected length product.The cross tabulation showed that prognosis and combination medication had significant difference（P〈0.05）.CONCLUSION Resistance to carbapenem of OXA-51（66）positive and negative expression provides the basis for the treatment of clinical medicine,detection of gene sequence has a certain clinical value for clinical combination medication.